Article type: Letter to Editor
Article title: The effect of “liquid gold” levodopa-carbidopa ascorbic acid solution in patients with Parkinson’s disease
Journal: Annals of Movement Disorders
Year: 2023
Authors: Jamir Pitton Rissardo, Ana Letícia Fornari Caprara
E-mail: jamirrissardo@gmail.com
ABSTRACT
Here, we wish to discuss the liquid levodopa-carbidopa ascorbic acid solution (LCAS), also known as citridopa, for the management of Parkinson's disease. The alkaline environment of these medications decreases the absorption of levodopa. In this way, acidic compounds such as ascorbic acid can increase the absorption of this drug and prevent its oxidation. In addition, the liquid forms of levodopa may facilitate its absorption due to increased surface area and distribution uniformity. Moreover, patients with advanced PD may experience possible delayed gastric emptying, and in such patients, liquid forms of LCAS are more tolerable than solid forms.
Keywords: Liquid; levodopa; citridopa; water-soluble; water-dispersible
Full text available at:
DOI
10.4103/aomd.aomd_42_22
Citation
Rissardo JP, Fornari Caprara AL. The effect of “liquid gold” levodopa–carbidopa ascorbic acid solution in patients with Parkinson’s disease. Ann Mov Disord 2023;6:111-3.
